Roche Pharmaceutical Development and Sales Overview

Roche gRED immunology and ophthalmology development programs Molecule Indication Phase # of patients Status Immunology CT Identifier efmarodocokin alfa (IL-22Fc, RG7880) aGVHD lb 18 FPI Q4 2020 NCT04539470 FPI Q1 2020 Inflammatory bowel disease | 68 NME (RG6287, GDC-8264) Recruitment completed Q3 2021 EUDRACT201 9-002613-19 Inflammatory diseases 16 FPI Q4 2021 NME (RG6315, MTBT1466A) Immunologic disorders | ~24 FPI Q3 2020 astegolimab (Anti-ST2, Chronic obstructive pulmonary llb 930 FPI Q4 2021 NCT05037929 (RG6149, AMG 282, MSTT1041A)1 disease NME (RG6341, GDC-6599) Asthma la/lb 84 FPI Q4 2021 Ophthalmology NME (RG6312) Geographic atrophy la NME (RG6351) Retinal disease Partner: 1Amgen 63 FPI Q4 2020 42-78 FPI Q2 2022 NCT04615325 139

View entire presentation